Single-Dose Malaria Drug Could Save 610,000 Lives Yearly

A single pill could soon replace weeks of malaria treatment for millions of people in tropical regions, thanks to a game-changing discovery from the University of Dundee.

Researchers there have developed cabamiquine, a novel compound that treats malaria in just one dose when combined with an existing drug called pyronaridine. Early trials involving adults and teenagers showed the combination works effectively with a strong safety profile, giving hope to communities where malaria kills more than 610,000 people every year.

The breakthrough comes at a critical time. Malaria cases reached 282 million in 2024, with numbers climbing partly because the disease is growing resistant to current medications. Most victims live in tropical countries where consistent healthcare access remains a challenge.

That's exactly why the single-dose approach matters so much. Current malaria treatments require multiple pills over several days, making it difficult for patients in remote areas to complete the full course. Dr. Beatriz Baragana, who helped discover cabamiquine, explains that simplified dosing could transform care for a disease causing hundreds of thousands of deaths annually.

Professor Ian Gilbert, who leads Dundee's drug discovery unit, emphasized the real-world impact. The compound's effectiveness combined with its one-dose delivery addresses the practical challenges of treating a disease in areas where healthcare delivery can be inconsistent.

The Ripple Effect

This discovery could reshape malaria control worldwide. Medicines for Malaria Venture, which funded the initial research, plans to advance cabamiquine-pyronaridine into larger trials and test it in children next.

Paul Willis from the organization stressed that novel treatments with simplified dosing are urgently needed to support long-term malaria elimination goals. The easier a treatment is to deliver, the more people it can reach in underserved communities.

The trial was conducted by pharmaceutical firm Merck as part of the PAMAfrica consortium, with funding from the European Union and Swedish development agencies. Results appeared in The Lancet Infectious Diseases, marking another step forward in the global fight against this ancient disease.

All the groundwork for cabamiquine happened in Dundee, demonstrating how university research can translate into real-world medical solutions. The team collaborated with scientific partners specifically to address unmet medical needs in resource-limited settings.

For the millions affected by malaria each year, this single pill represents more than scientific progress—it's a pathway to survival that finally fits the reality of their lives.